Increased incidence of diabetes seen among patients aged younger than 18 years after acute COVID-19 infection versus those without COVID-19
BNT162b2 Vaccine Effective Against Severe COVID-19 in Adolescents
Two doses highly effective against COVID-19-related hospitalization and critical illness for those aged 12 to 18 years
Two Doses of BNT162b2 Vaccine Protect Against MIS-C
Two doses of Pfizer-BioNTech vaccine have estimated effectiveness of 91 percent against MIS-C in children aged 12 to 18 years
Young Adults With Cancer Facing Psychological Distress During Pandemic
High psychological distress tied to lower quality of life, social isolation, impaired cancer care
Effect of Types of Screen Use on Child Mental Health Examined
Different types of screen use during the pandemic associated with distinct mental health symptoms in children according to age group
COVID-19 Vaccines Significantly Cut MIS-C Risk in Teens
Of 107 children hospitalized with multisystem inflammatory syndrome in children, none were fully vaccinated
CDC Backs FDA Approval of Boosters for Those Aged 12 to 17 Years
In arriving at its decision, the CDC advisory panel pointed to rising COVID-19 hospitalizations among the young
FDA Approves Pfizer Booster Shots for Children Ages 12 to 15
Agency also reduced the period people must wait between their second dose and booster shot from six to five months
FDA May Allow Pfizer Boosters for 12- to 15-Year-Olds by Monday
Agency also expected to reduce the amount of time adolescents and adults must wait between their second dose of vaccine and booster
BNT162b2 Vaccine Effectiveness 92 Percent for Teens Ages 12 to 17
Estimated vaccine effectiveness of full Pfizer-BioNTech vaccination 92 percent for preventing SARS-CoV-2 infection